Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
envafolimab + trastuzumab + docetaxel
- Development stage
- Phase 2
- Lead developer
- 3D Medicines (Sichuan) Co., Ltd.
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Subcutaneous, Intravenous
01
Overview
Envafolimab + trastuzumab + docetaxel is an investigational combination therapy being evaluated for the treatment of HER2-positive breast cancer. The regimen consists of **envafolimab** (KN035), a unique subcutaneous PD-L1 single-domain antibody Fc fusion protein; **trastuzumab**, a monoclonal antibody targeting the human epidermal growth factor receptor 2 (HER2); and **docetaxel**, a taxane-based chemotherapy agent. Envafolimab is designed to block the interaction between PD-L1 and PD-1, thereby restoring T-cell-mediated anti-tumor immune responses. Trastuzumab inhibits tumor cell proliferation by binding to the extracellular domain of HER2 and mediating antibody-dependent cellular cytotoxicity (ADCC). Docetaxel acts by stabilizing microtubules and inhibiting their disassembly, leading to cell cycle arrest and apoptosis. This combination is currently being studied in Phase II clinical trials sponsored by Sun Yat-Sen Memorial Hospital to assess its efficacy and safety in patients with HER2-positive disease.
- Other names
- KN035 + trastuzumab + docetaxel
02
Targets
ERBB2 (Erb-b2 receptor tyrosine kinase 2)CD274 (Programmed cell death protein 1 ligand 1)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on envafolimab + trastuzumab + docetaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on envafolimab + trastuzumab + docetaxel.